https://doi.org/10.55788/03b66a14
“Prof. Goadsby is the type of clinician-scientist who nearly single-handedly by this pursuit changed the treatment paradigm in the field of migraine by advancing insights into the pathophysiology of a complex disease that was already believed to have been understood” [1]. These introductory words came from Prof. Natalia Rost (Massachusetts General Hospital, MA, USA). In his following lecture, Prof. Goadsby described the current armamentarium of migraine medications, including triptans, monoclonal antibodies, gepants, ditans, and neuromodulation techniques, and the underlying biology. He stressed the importance of including participants in migraine clinical trials who have previously failed on other agents, not only because they lower placebo rates, but also because these are the patients you often encounter in clinical practice.
One of the central ideas Prof. Goadsby discussed was that of migraine as a network disorder with many targets. “Migraine is typically thought of as a linear process. I think that is a too-limited view of what is a complex, networked neurological disorder. Think of the phases of migraine not linearly but as integrated; think of the symptomatology as a totality.” He advised the audience to go through all symptomatology with patients. “Put it in people's minds. It only takes about 5 minutes extra.”
According to Prof. Goadsby, prodromal (premonitory) migraine symptoms are easily confused with triggers. For example, about 5% of patients experience photophobia in the prodromal phase, so they will often consider light a trigger. Or they experience food cravings in the prodromal phase and assume food to be a trigger when it is, in fact, a prodromal symptom. “A patient can feel empowered just by hearing this explanation.”
A possible paradigm shift Prof. Goadsby predicted, centred around pituitary adenylate cyclase-activating polypeptide (PACAP). This is a secretin/glucagon superfamily peptide with a saturable transport system into the brain. Research by Prof. Goadsby and others from the past 30 years revealed that PACAP is elevated in migraine without aura and can be normalised with sumatriptan [1]. These data already suggested that PACAP (or its receptors) could be a promising target for migraine therapeutics.
Only a few days before the lecture by Prof. Goadsby, positive phase 2 proof-of-concept results of the HOPE trial (NCT05133323) on Lu AG09222 in migraine prevention were announced [2]. Lu AG09222 is a monoclonal antibody that binds and inhibits signalling mediated by the pituitary adenylate cyclase-activating polypeptide (PACAP). The double-blind, placebo-controlled HOPE trial assessed the efficacy, safety, and tolerability of a single intravenous infusion of Lu AG09222 in 237 migraine patients. It resulted in significantly fewer monthly migraine days in weeks 1–4 compared with placebo (P=0.01). The full trial results are not yet available.
Another paradigm shift could be using gepants in the prodromal stage of migraine. This was precluded by results of the UBR PRODROME study (NCT04492020) presented at the AAN 2023 meeting [3]. This placebo-controlled cross-over study evaluated the efficacy, safety, and tolerability of ubrogepant 100 mg when administered during the prodrome of a migraine attack. Participants treated 2 events that qualified as prodromal, meaning they were confident a headache would follow these events between 1 and 6 hours later. In 477 participants, 45.5% of treated prodromal events in the ubrogepant group were followed by the absence of moderate/severe headache within 24 hours, compared with 28.6% of events in the placebo group (P<0.0001). The number of symptoms and time to absence after treatment were also shorter than with a placebo. Prof. Goadsby: “Why is this important? Because 75% of people have some form of disability during the prodromal phase of migraine. That is what we neurologists are about, namely treating people with disabling problems.”
- Goadsby P. Migraine: then, now, and tomorrow - progress through biology. PL3.004, AAN 2023 Annual Meeting, 22–27 April, Boston, USA.
- H. Lundbeck A/S. Lundbeck announces positive phase 2 Proof of Concept results with Lu AG09222 in migraine prevention. Corporate press release, 19 April 2023.
- Dodick DW, et al. Ubrogepant for the acute treatment of migraine when administered during the prodrome (premonitory phase): Results from a phase 3, randomized, double-blind, placebo-controlled, crossover study. S47.001, AAN 2023 Annual Meeting, 22–27 April, Boston, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Zavegepant nasal spray exhibits good efficacy and safety in acute migraine Next Article
Ravulizumab effective in AQP4+ NMOSD »
« Zavegepant nasal spray exhibits good efficacy and safety in acute migraine Next Article
Ravulizumab effective in AQP4+ NMOSD »
Table of Contents: AAN 2023
Featured articles
Letter from the Editor
Positive results for hereditary transthyretin-mediated amyloid polyneuropathy
Infectious Diseases
Allogenic T-cell-based immunotherapy for PML in development
Cognitive Impairment and Dementia
Lecanemab may slow decline of cognition and function in Alzheimer’s Disease
Donanemab shows rapid and deep plaque clearance in early Alzheimer’s Disease
Epilepsy
Seizure forecasting and detection with wearable devices are feasible
Encouraging first results of GABAergic interneurons implants for focal epilepsy
Headache and Migraine
Lecture on migraine: from the prodromal phase to future paradigm shifts
Zavegepant nasal spray exhibits good efficacy and safety in acute migraine
A vaccine as a potentially safe and effective immunotherapy against CGRP
Multiple Sclerosis
Teriflunomide prevents conversion to MS in patients with RIS
Gold nanocrystals may be effective as adjunctive MS therapy
Muscle and Neuro-Muscular Disorders
First-ever ALS platform trial reports on outcomes of 4 treatments
Pridopidine for Huntington’s disease fails to meet the primary endpoint
Parkinson's Disease
Continuous levodopa/carbidopa infusion shows favourable safety and efficacy
Unilateral right STN-DBS improves verbal fluency
Stroke
Harnessing the microbiome as a possible stroke treatment
Patients with a large core infarct benefit from thrombectomy
Miscellaneous
Artificial intelligence applications in neurology: seize the moment
Spinal cord stimulation eases painful diabetic neuropathy
EVT improves functional outcomes in Chinese patients with BAO
Severe sleep apnoea associated with white matter hyperintensities
Related Articles
October 30, 2022
In the spotlight: Cancer trends in obstructive sleep apnoea
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com